Tempus AI (NASDAQ:TEM) Shares Down 14.5% Following Insider Selling

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price dropped 14.5% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $72.25 and last traded at $73.25. Approximately 12,344,723 shares changed hands during trading, a decline of 13% from the average daily volume of 14,108,291 shares. The stock had previously closed at $85.71.

Specifically, CFO James William Rogers sold 31,780 shares of Tempus AI stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $82.33, for a total value of $2,616,447.40. Following the sale, the chief financial officer now owns 189,320 shares of the company's stock, valued at approximately $15,586,715.60. The trade was a 14.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Erik Phelps sold 61,582 shares of Tempus AI stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $82.36, for a total value of $5,071,893.52. Following the completion of the sale, the executive vice president now directly owns 153,080 shares in the company, valued at $12,607,668.80. This represents a 28.69 % decrease in their position. The disclosure for this sale can be found here. In other Tempus AI news, CAO Ryan M. Bartolucci sold 818 shares of Tempus AI stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $81.87, for a total value of $66,969.66. Following the sale, the chief accounting officer now owns 46,182 shares of the company's stock, valued at approximately $3,780,920.34. The trade was a 1.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Analysts Set New Price Targets

TEM has been the topic of a number of analyst reports. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective on the stock. Stifel Nicolaus lowered Tempus AI from a "buy" rating to a "hold" rating and boosted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital decreased their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Tuesday, January 14th. Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They set a "buy" rating and a $74.00 price target on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of "Moderate Buy" and an average target price of $58.55.

Tempus AI Stock Performance

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business has a 50 day moving average of $50.29 and a 200-day moving average of $51.72.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in Tempus AI in the 4th quarter valued at $108,000. Voloridge Investment Management LLC acquired a new position in Tempus AI in the 4th quarter valued at $11,826,000. Two Sigma Advisers LP acquired a new position in Tempus AI in the 4th quarter valued at $625,000. ProShare Advisors LLC acquired a new position in Tempus AI in the 4th quarter valued at $244,000. Finally, Lazard Asset Management LLC acquired a new position in Tempus AI in the 4th quarter valued at $1,034,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.